Selpercatinib for Solid Tumors and Lymphomas
Trial Summary
Do I need to stop my current medications to join the trial?
The trial requires that you stop taking certain medications before joining. You cannot be on other anti-cancer agents, investigational drugs, or medications that affect the CYP3A4 enzyme. If you are on corticosteroids, you need to be on a stable or decreasing dose for at least 7 days before enrolling.
Is selpercatinib safe for humans?
What makes the drug Selpercatinib unique for treating solid tumors and lymphomas?
Selpercatinib is unique because it is a highly selective inhibitor that targets RET kinase, which is involved in certain genetic alterations found in some cancers. It is taken orally and has shown effectiveness in treating cancers with RET alterations, such as non-small cell lung cancer and thyroid cancer, offering a targeted approach compared to traditional chemotherapy.12567
What is the purpose of this trial?
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.
Research Team
Andrea T Franson
Principal Investigator
Children's Oncology Group
Eligibility Criteria
This trial is for children and young adults up to 21 years old with advanced solid tumors, lymphomas, or histiocytic disorders that have specific RET gene changes. They must be in good physical condition with adequate organ function and not have been treated with selpercatinib before. Pregnant or breastfeeding individuals, those who've had major surgery recently, or are on certain medications affecting the immune system can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive selpercatinib orally twice daily on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up for 30 days and periodically thereafter.
Treatment Details
Interventions
- Selpercatinib
Selpercatinib is already approved in United States, European Union for the following indications:
- RET fusion-positive or RET mutant thyroid cancers
- non-small cell lung cancer
- advanced or metastatic medullary thyroid cancer
- advanced or metastatic thyroid cancer with RET gene fusion
- locally advanced or metastatic solid tumors with RET gene fusion
- RET-driven non-small cell lung cancer
- medullary thyroid cancer
- thyroid cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor
Children's Oncology Group
Collaborator